Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxNovel Preclinical Drug Could Have Potential to Combat Depression, Brain Injury and Cognitive Disorders

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form